2NTX-99 is a novel small molecule that has been shown in vivo and in vitro to inhibit the synthesis and action of thromboxane (TXA2), enhance the production of endothelial prostacyclin (PGI2) and supply a pharmacological amount of nitric oxide (NO) to the vasculature. Nile believes that the unique activity profile of 2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.
More information on Nile can be found at http://www.nilethera.com.
Chief Financial Officer
Nile Therapeutics, Inc.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, future operations, outlook, milestones, the success of Nile's
product development, future financial position, future financial results,
plans and objectives of management are forward-looking statements. We may
not actually achieve these plans, intentions or expectations and Nile
cautions investors not to place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements we make. Various important factors that could cause actual
results or events to differ materially from the forward-looking statements
|SOURCE Nile Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved